NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Sell
27
LXRX Quote, Financials, Valuation and Earnings
Last price:
$0.82
Seasonality move
:
5.4%
Day range:
$0.70 - $0.76
52-week range:
$0.62 - $3.73
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
39.74x
P/B ratio:
1.45x
Volume:
7M
Avg. volume:
4.6M
1-year change:
-41.42%
Market cap:
$258.4M
Revenue:
$1.2M
EPS (TTM):
-$0.75
Analysts' Opinion
-
Consensus RatingLexicon Pharmaceuticals has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $3.60, Lexicon Pharmaceuticals has an estimated upside of 403.71% from its current price of $0.71.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $0.80 representing -11.94% downside risk from its current price of $0.71.
Fair Value
-
According to the consensus of 4 analysts, Lexicon Pharmaceuticals has 403.71% upside to fair value with a price target of $3.60 per share.
LXRX vs. S&P 500
-
Over the past 5 trading days, Lexicon Pharmaceuticals has underperformed the S&P 500 by -10.01% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Lexicon Pharmaceuticals does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Lexicon Pharmaceuticals has grown year-over-year revenues for 6 quarters straight. In the most recent quarter Lexicon Pharmaceuticals reported revenues of $1.8M.
Earnings Growth
-
Lexicon Pharmaceuticals has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Lexicon Pharmaceuticals reported earnings per share of -$0.18.
Enterprise value:
99.9M
EV / Invested capital:
0.36x
Price / LTM sales:
39.74x
EV / EBIT:
--
EV / Revenue:
19.10x
PEG ratio (5yr expected):
-0.15x
EV / Free cash flow:
-0.48x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$4.9M
Return On Assets:
-66.89%
Net Income Margin (TTM):
-4138.33%
Return On Equity:
-115.11%
Return On Invested Capital:
-75.24%
Operating Margin:
-3639.6%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $125K | $531K | $5.2M | $162K | $1.8M | |
| Gross Profit | -- | $516K | $4.9M | $155K | $1.7M | |
| Operating Income | -$95.8M | -$155.3M | -$211.1M | -$49.6M | -$63.7M | |
| EBITDA | -$94.7M | -$148.6M | -$198.7M | -$46.5M | -$60.1M | |
| Diluted EPS | -$0.62 | -$0.76 | -$0.75 | -$0.21 | -$0.18 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $121.9M | $124M | $139.1M | $223.4M | $268.6M | |
| Total Assets | $178.9M | $172.3M | $191.7M | $276.5M | $321.1M | |
| Current Liabilities | $78.9M | $34.2M | $18.4M | $32.3M | $36M | |
| Total Liabilities | $91.3M | $35.7M | $47.7M | $137M | $142.6M | |
| Total Equity | $87.6M | $136.6M | $144M | $139.5M | $178.5M | |
| Total Debt | $20.3M | $11.7M | $23.8M | $99.3M | $99.9M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$90.1M | -$132.9M | -$207.8M | -$41.6M | -$53.6M | |
| Cash From Investing | -$89.2M | -$77.7M | -$17.2M | -$39.3M | $53.5M | |
| Cash From Financing | $106M | $212.9M | $238.5M | -$210K | -$916K | |
| Free Cash Flow | -$90.2M | -$134.6M | -$208.4M | -$41.7M | -$53.9M | |
LXRX
Sector
Market Cap
$258.4M
$43.9M
Price % of 52-Week High
19.16%
45.73%
Dividend Yield
0%
0%
Shareholder Yield
0.25%
-0.74%
1-Year Price Total Return
-41.42%
-29.11%
Beta (5-Year)
1.069
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$0.77
200-day SMA
Sell
Level
$1.68
Bollinger Bands (100)
Sell
Level
1.01 - 1.87
Chaikin Money Flow
Sell
Level
-121.8M
20-day SMA
Sell
Level
$0.76
Relative Strength Index (RSI14)
Sell
Level
37.03
ADX Line
Buy
Level
10.74
Williams %R
Neutral
Level
-76.4014
50-day SMA
Sell
Level
$1.20
MACD (12, 26)
Sell
Level
-0.11
25-day Aroon Oscillator
Sell
Level
-52
On Balance Volume
Neutral
Level
448.8M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-10.7276)
Sell
CA Score
(Annual)
Level (-3.9713)
Sell
Beneish M-Score
(Annual)
Level (6.848)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (5.0803)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.
Stock Forecast FAQ
In the current month, LXRX has received 2 Buy ratings 2 Hold ratings, and 0 Sell ratings. The LXRX average analyst price target in the past 3 months is $3.60.
-
Where Will Lexicon Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that Lexicon Pharmaceuticals share price will rise to $3.60 per share over the next 12 months.
-
What Do Analysts Say About Lexicon Pharmaceuticals?
Analysts are divided on their view about Lexicon Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Lexicon Pharmaceuticals is a Sell and believe this share price will drop from its current level to $0.80.
-
What Is Lexicon Pharmaceuticals's Price Target?
The price target for Lexicon Pharmaceuticals over the next 1-year time period is forecast to be $3.60 according to 4 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is LXRX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Lexicon Pharmaceuticals is a Buy. 2 of 4 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of LXRX?
You can purchase shares of Lexicon Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Lexicon Pharmaceuticals shares.
-
What Is The Lexicon Pharmaceuticals Share Price Today?
Lexicon Pharmaceuticals was last trading at $0.82 per share. This represents the most recent stock quote for Lexicon Pharmaceuticals. Yesterday, Lexicon Pharmaceuticals closed at $0.71 per share.
-
How To Buy Lexicon Pharmaceuticals Stock Online?
In order to purchase Lexicon Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 23
Quantum [QMCO] is up 3.65% over the past day.
Sell
46
NUKK alert for Dec 23
Nukkleus [NUKK] is up 4.9% over the past day.
Sell
1
IIPR alert for Dec 23
Innovative Industrial Properties [IIPR] is down 4.4% over the past day.
